Modrall et al 1 Modrall G.J. Zhu H. Prasad T. Moe O. Dworkin L.D. Cutlip D.E. et al. Retrieval of renal function after renal artery stenting improves event-free survival in a subgroup analysis of the cardiovascular outcomes in renal atherosclerotic lesions trial.. J Vasc Surg. 2023; 77: 1685-1692 Abstract Full Text Full Text PDF Scopus (1) Google Scholar have reanalyzed data from the CORAL trial 2 Cooper C.J. Murphy T.P. Cutlip D.E. Jamerson K. Henrich W. Reid D.M. et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med. 2014; 370: 13-22 Crossref PubMed Scopus (666) Google Scholar to identify a role for renal artery stenting (RAS) in the subset of patients with chronic kidney disease (CKD). They demonstrated, again, that stenting does not provide a benefit compared with optimal medical therapy in terms of event-free survival, the primary end point of their analysis and the parent trial. The blood pressure response was similar between their groups, although the change in serum creatinine and the percentage of change in the estimated glomerular filtration rate (eGFR) were better in the stented group, albeit modest. A larger percentage of the stented patients had had a ≥20% increase in their eGFR (responders) vs the medical group (25.6% vs 17.1%), although the percentage of those with a ≥20% decrease in the eGFR was similar. These responders had had improved event-free, non–renal event-free, and overall survival compared with the nonresponders. However, the presence of diabetes (negative) was the only predictor of a good response. Retrieval of renal function after renal artery stenting improves event-free survival in a subgroup analysis of the Cardiovascular Outcomes in Renal Atherosclerotic Lesions trialJournal of Vascular SurgeryVol. 77Issue 6PreviewThe Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) trial, a multicenter randomized controlled trial with 947 patients, concluded that there was no benefit of renal artery stenting (RAS) over medical therapy. However, patients with chronic kidney disease (CKD) were not analyzed separately in the CORAL trial. CKD is a risk factor for cardiovascular and renal morbidity. We hypothesized that improved renal function after RAS would be associated with increased long-term survival and a lower risk of cardiovascular and renal events in patients with CKD. Full-Text PDF